Dangerously Thin: A Case Study On The Genetic Code At 65 Yea

Dangerously Thin: A Case Study on the Genetic Code at 65 Years Old Hen

Henry Blake, a 65-year-old retired man, faced a complication after returning from a trip to Australia. He experienced swelling in his leg, which was diagnosed as deep vein thrombosis (DVT). He was prescribed warfarin, a blood-thinning medication, but developed excessive bleeding, raising concerns about his response to the drug. Blood tests showed abnormal clotting times, prompting genetic testing that revealed Henry carried two mutated copies of the CYP2C9 gene. These mutations impaired the enzyme's ability to metabolize warfarin, classifying him as a poor metabolizer. This case explores the genetic basis of drug metabolism, the impact of mutations on enzyme function, and the broader implications for personalized medicine.

Sample Paper For Above instruction

Henry Blake's case exemplifies the critical role of genetics in determining individual responses to pharmaceutical treatments. His experience with excessive bleeding after warfarin therapy underscores how genetic variations can significantly influence drug metabolism and efficacy. This paper examines the genetic mutation in CYP2C9, its impact on enzyme function, and the broader implications for personalized medicine.

Understanding the genetic foundation of drug metabolism begins with the role of enzymes such as CYP2C9. Located in the cytochrome P450 family, CYP2C9 is pivotal in the oxidative metabolism of various drugs, including warfarin. The efficiency of this enzyme determines how quickly a drug is broken down, influencing both its therapeutic effect and risk of side effects. In Henry's case, mutations in both copies of the CYP2C9 gene resulted in a deficiency of functional enzyme. Consequently, he was classified as a poor metabolizer, leading to slower clearance of warfarin from his system. This impaired enzyme activity caused elevated blood concentrations of the drug, resulting in an increased risk of bleeding complications, which is consistent with the observed frequent nosebleeds and abnormal INR levels.

The core issue stems from mutations in the coding regions of Henry's CYP2C9 genes. The first mutation involved a nucleotide change from adenine (A) to cytosine (C) at position 1075, affecting the triplet ATT, which normally encodes the amino acid isoleucine. This mutation alters the triplet to CTT, which encodes leucine. Such a change can influence the enzyme's structure by substituting one amino acid for another, potentially destabilizing the protein or impairing its catalytic activity. The second mutation involves a cytosine (C) to thymine (T) change at position 430, transforming the triplet CGT (arginine) to TGT (cysteine). Both mutations are missense mutations, which result in amino acid substitutions that can disrupt the enzyme's normal configuration and function. These changes diminish the enzyme's ability to effectively metabolize warfarin, leading to higher plasma levels and increased bleeding risk.

Gene expression relies on the accurate transfer of genetic information from DNA to RNA and then to protein. The DNA coding strand is a sequence that contains the same nucleotide sequence as the mRNA, except that thymine (T) in DNA is replaced by uracil (U) in mRNA during transcription. The coding strand is complementary to the template strand, which provides the sequence that is read by RNA polymerase during transcription. Mutations in the coding strand directly alter the sequence of mRNA and subsequently the structure of the synthesized protein. In Henry's case, the mutations in the coding strand lead to amino acid substitutions in the CYP2C9 enzyme, impairing its function. The difference between the coding and template strands lies in their role: the coding strand mirrors the mRNA sequence, while the template strand serves as the template for transcription.

Analyzing a segment of Henry's CYP2C9 gene with the sequence TTACCGAGA, we find that its complementary template strand would be AATGGCTCT. This segment contains three triplet codes: TTA, CCG, and AGA. During transcription, this sequence would produce an mRNA sequence of AAUGGC UCU. The triplet codes in mRNA correspond to specific amino acids, and in this case, the sequence encodes for two amino acids: leucine (TTA) and arginine (AGA), with the middle triplet CCG coding for proline. The entire portion of the coding strand would instruct the synthesis of a short peptide, possibly serving a structural or functional role within the enzyme.

The mutation of the 1075th nucleotide from adenine (A) to cytosine (C) changes the DNA triplet from ATT to CTT. On the template strand, this triplet corresponds to the mRNA codon AAU changing to CUC after transcription. The anticodon on the tRNA would be GAG, complementing the mRNA codon CUC. The amino acid specified by CUC is leucine, replacing isoleucine originally encoded by ATT. This substitution can alter the enzyme's three-dimensional structure, potentially disrupting its active site or stability, resulting in reduced metabolic activity.

The second mutation, changing the nucleotide at position 430 from C to T, converts the triplet CGT into TGT. The corresponding mRNA codon becomes GCA, which codes for alanine instead of arginine. Its anticodon would be UCG, pairing with the mRNA GCA. This amino acid substitution could affect the enzyme's tertiary structure, especially if it occurs near the active site or within a domain critical for substrate binding. The cumulative effect of these mutations reduces the enzyme's ability to process drugs like warfarin efficiently.

Enzymes are biological catalysts that facilitate chemical reactions by lowering activation energy. Their function depends heavily on their three-dimensional structure, specifically the shape and properties of the active site where substrate molecules bind. An amino acid substitution caused by a genetic mutation can alter the enzyme's structure, potentially modifying the shape, charge, or hydrophobicity of the active site. Such structural changes can diminish the enzyme's catalytic efficiency or render it inactive, as seen in Henry's case with CYP2C9. The loss of enzymatic function prevents proper metabolism of warfarin, leading to accumulation in the bloodstream and heightened bleeding risk. Therefore, even a single amino acid change can significantly impair enzyme activity, influencing drug response (Rowland & Tozer, 2010).

Considering the genetic code's redundancy, multiple codons can encode the same amino acid, offering a buffer against mutations. Changes in the third nucleotide position, called the wobble position, often do not alter the amino acid specified. For instance, the four codons GCA, GCG, GCU, and GCC all encode alanine. Mutations in these third positions may, therefore, be silent, not affecting enzyme function. For the mutations in Henry's genes, analyzing the genetic code chart reveals that some nucleotide substitutions could result in synonymous (silent) mutations, which do not change the amino acid. For example, a mutation in the third nucleotide of CGT could change it to CGC or CGA, both encoding arginine. By contrast, mutations at the first nucleotide position, as in Henry’s case, are more likely to lead to amino acid substitutions, which can impact enzyme activity (Hartl & Ruvolo, 2016).

From Henry's case, it becomes clear that the specific location of mutations within a triplet codon is crucial. Changes in the first or second nucleotide often result in amino acid substitutions, potentially disrupting protein function. Conversely, certain changes in the third nucleotide can be silent because of the redundancy in the genetic code. This pattern highlights the importance of mutation position in predicting the impact on protein function and drug metabolism. Understanding these nuances guides personalized medicine approaches, allowing clinicians to tailor drug dosages based on genetic profiles, minimizing adverse effects and optimizing efficacy (Kumar et al., 2018). In Henry’s scenario, his genetic makeup necessitated a reduced warfarin dosage and closer monitoring, illustrating the importance of pharmacogenomics in clinical practice.

References

  • Rowland, M., & Tozer, T. N. (2010). Clinical pharmacokinetics and pharmacodynamics: Concepts and applications. Lippincott Williams & Wilkins.
  • Hartl, D. L., & Ruvolo, M. (2016). Genetics: Principles and analysis. Jones & Bartlett Learning.
  • Kumar, S., et al. (2018). Pharmacogenomics of anticoagulant therapy: guidelines and implications. Pharmacogenomics Journal, 18(4), 327-335.
  • Johnson, J. A. (2014). Pharmacogenetics: Impact on drug development and clinical practice. Journal of Clinical Oncology, 32(30), 3240–3242.
  • Sim, S. C., et al. (2012). Genetic factors influencing warfarin dosage. Nature Reviews Cardiology, 9(3), 155-167.
  • Perera, M. A., et al. (2014). Genes involved in warfarin response: Pharmacogenetics and clinical implications. Pharmacogenetics and Genomics, 24(4), 181-192.
  • Klein, T. E., et al. (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. New England Journal of Medicine, 360(8), 753-764.
  • Gong, L., et al. (2015). CYP2C9 and VKORC1 genotypes and warfarin dose requirements. Pharmacogenetics & Genomics, 25(10), 509-519.
  • Johnson, J. A., et al. (2019). Improving personalized medicine through pharmacogenomics. Nature Reviews Drug Discovery, 18(6), 477-495.
  • O'Reilly, R. A., et al. (2017). Enzyme polymorphisms and drug metabolism: clinical relevance. Pharmacology & Therapeutics, 172, 137-145.

Related Assignments